Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U.S. sales of Cosentyx, as well ...

Novartis posted third-quarter results that beat analysts' estimates and raised its full-year outlook, buoyed by strong sales ...

Novartis’ Kisqali (ribociclib) has been recommended by the European Medicines Agency’s human medicines committee to reduce the risk of recurrence in early breast cancer patients. The Committee for ...

Novartis AG (NYSE:NVS) raised its full-year guidance for the third time, indicating strong underlying business momentum. Key ...

NVS' third-quarter earnings and sales beat estimates. Based on the strong momentum of key drugs, the company raises its ...

Novartis reported strong third-quarter sales of $12.823 billion, beating consensus, with key growth drivers contributing to momentum and upgraded guidance for 2024.

As expected, Novartis’ radioligand therapy Pluvicto crossed the blockbuster sales threshold with one quarter still left of 2024. | Novartis didn't use a priority review voucher for Pluvicto's key ...

Meanwhile, Novartis has gained two new FDA approvals in the US for its breast cancer drug Kisqali and Fabhalta which is used ...

Novartis AG ( (NVS) ) has realeased its Q3 earnings. Here is a breakdown of the information Novartis AG presented to its investors. Novartis AG ...